Aileron Therapeutics (ALRN) Receives a Rating Update from a Top Analyst

By Austin Angelo

H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics (ALRNResearch Report) today and set a price target of $2.00. The company’s shares closed last Monday at $1.14.

According to, White is a top 100 analyst with an average return of 29.1% and a 54.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Aileron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.99 and a one-year low of $0.25. Currently, Aileron Therapeutics has an average volume of 978.4K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALRN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.